Latest Mycophenolic acid Stories
COLUMBUS, Ohio, May 4 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the launch of its generic for Mycophenolate Mofetil 250mg Capsules and 500mg Tablets by the U.S. Food and Drug Administration.
Study Suggests Genetic Approach to Personalized Screening of Anti-Rejection Drug Dosing CINCINNATI, Feb.
Biotech company Pharming Group has announced that the FDA has authorized a clinical study with recombinant human C1 inhibitor for the treatment of antibody-mediated rejection in kidney transplantation.
Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today that the US Food and Drug Administration (FDA) has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection (AMR) in kidney transplantation.
COLUMBIA, Md., Aug.
Chinese scientists say a treatment using several drugs targeting various parts of the immune system helps patients with severe lupus involving the kidneys.
TORONTO, June 1 /PRNewswire/ -- The final results of the Spare the Nephron (STN) study, a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil), showed the CellCept-based regimen in combination with sirolimus (SRL) is associated with improved renal function when compared with the CellCept-based regimen in combination with calcineurin inhibitors (CNI).
Reportlinker.com announces that a new market research report related to the Health Care industry is available in its catalogue.
By Stewart, Susan Context.-Pulmonary infections are common and often life- threatening in solid organ and stem cell transplant recipients.
By McCalmont, Vicki Bennett, Kristi Progressive multifocal leukoencephalopathy is a rare, highly fatal demyelinating brain infection caused by the JC virus. This infection is associated with immunosuppressive agents and is emerging in the transplant population.